Article

HPLC purity vs net peptide content: two numbers that are often confused

Published 21 October 2026 · DesignPeptide Research Desk

Abstract chromatogram peaks beside a segmented bar showing the parts of a weighed powder

Prepared by: Research Desk. Sources are linked for verification.

Published 21 October 2026

Two questions, two numbers

A certificate of analysis (COA) for a synthetic peptide often carries two figures that look alike but answer different questions. HPLC purity asks what share of the material the detector can see belongs to the main peak. Net peptide content asks how much of the weighed powder is actually peptide.

The gross mass of a peptide powder can include water, residual solvent, salts and counterions. A batch can therefore show high chromatographic purity and still have a lower peptide content by weight. For background on how batches are made and tested, see the guide to how research peptides are made and tested.

What area-percent purity measures

High-performance liquid chromatography (HPLC) passes a dissolved sample through a column. For peptides this normally means a column with a non-polar stationary phase, which separates peptide-related species by hydrophobicity. A detector records each component as a peak on a chromatogram.

The purity figure is the area of the main peak as a percentage of the total detected peak area. It is a relative figure that compares peaks with one another. It is not the peptide's mass fraction and not a measure of the total chemical content of the sample.

Detection wavelength

Most peptide methods use ultraviolet (UV) detection. A wavelength near 214 nm is common because peptide bonds absorb strongly there, and 220 nm is also used. The chromatogram only shows what absorbs at the chosen setting, so a purity figure given without its wavelength is missing part of the information needed to interpret it.

Co-elution and response factors

Two effects limit what an area percentage can show.

  • Co-elution. Closely related impurities can leave the column at the same time as the main peak and be counted as part of it. A review of related impurities in peptide medicines describes the main types, including deletion and insertion sequences, incomplete deprotection, oxidation, deamidation and diastereomers (D'Hondt et al., 2014, PubMed). Some, such as epimers, share the nominal mass of the target. Their origins are covered on the synthetic peptide impurities page.
  • Response factors. Different compounds do not absorb UV light equally. A weakly absorbing impurity gives a smaller peak than its true amount would suggest; a strongly absorbing one gives a larger peak. Area percent quietly assumes similar responses, which is not always the case.

Net peptide content, counterions and water

The gross mass of a peptide powder can include water, residual solvent, salts and counterions such as trifluoroacetate (TFA), which is left over from purification, or acetate. These components do not show up in the UV chromatogram the way the peptide does, so they do not register in the purity figure in the same way, while still adding to the weighed mass.

Net peptide content (also called peptide content or assay, depending on the method) needs a separate measurement, such as amino acid analysis. A COA that reports it should state the basis of calculation and any correction for water or counterions.

Reading both on a COA

Points worth checking on a peptide COA:

  1. Purity: the result, method, detection wavelength and chromatographic conditions or a method reference. An attached chromatogram says more than a single number.
  2. Peptide content or assay: whether it is reported at all, the method and the basis of calculation.
  3. Counterion and water: the counterion named and, where relevant, quantified; water content and residual solvents stated where applicable.
  4. Identity: a mass spectrometry result with expected and observed mass. MS supports identity, not purity, and cannot distinguish all isomers.

A report showing only HPLC and MS says nothing about water, counterion content or the peptide fraction of the powder.

Worked example (illustrative)

The figures below are invented to show the arithmetic. They do not describe any real batch.

A COA lists HPLC purity 98% and net peptide content 80%.

  • Take 100 parts by weight of the powder as received.
  • Net peptide content indicates about 80 of those parts are peptide material.
  • The other 20 parts are non-peptide mass. In this made-up case, imagine roughly 12 parts counterion, 6 parts water and 2 parts residual solvent and salts.
  • The 98% purity figure applies to the UV-visible peptide-related material. If, as a simplifying assumption, peak area tracked mass among those species, about 98% of the 80 parts would be the target sequence: roughly 78 parts, with about 2 parts of detected peptide-related impurities.

So a batch labelled "98% pure" could be closer to 78% target peptide by weight. Neither figure is wrong; they measure different things. The 78-part estimate rests on the response-factor assumption and on how the content method counts related impurities, so it is an approximation, not a result.

Limitations

  • Both figures depend on method. Whether an HPLC method can separate and detect the relevant impurities is a question of validation. The ICH Q2(R2) guideline on validating analytical procedures, listed on the ICH quality guidelines page, covers specificity, accuracy and precision.
  • A COA describes the sample tested. It says something about other containers only if they come from the same, uniform batch.
  • Regulatory thresholds are product-specific. FDA's May 2021 guidance on certain highly purified synthetic peptides referring to listed drugs of rDNA origin (glucagon, liraglutide, nesiritide, teriparatide and teduglutide) generally recommends identifying peptide-related impurities at 0.10% or greater, and states that a new specified impurity above 0.5% is not acceptable for that approach (FDA guidance text; FDA presentation). These numbers apply to that narrow scope, not to every peptide.
  • Paperwork is not confirmation. Analytical work on seized falsified peptide products found impurity profiles that the documents did not reveal (Janvier et al., 2018, PubMed).
  • A research-use COA is not a drug-substance specification. It is an analytical record and says nothing about suitability for any use.

Supplier documentation

Purita is a store that sells peptides for laboratory research use only. It publishes a certificates page where reports are available for some products; reports are not yet available for every item, so check the page for the specific material.

Purita certificates page

Affiliate disclosure: this is a paid link. DesignPeptide earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the affiliate disclosure.

Related pages

More from DesignPeptide